Evidence map›Paper›PMID 42379171›Full record

Trial reportCell reports. Medicine2026

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

Huan Yan, Wenjuan Jiang, Yi Xiong, Li Liu, Renzhi Zhang, Zhaohui Ruan, Zhe Huang, Jiacheng Dai, Fang Tian, Chunhua Zhou and 8 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05379803 (A Single Arm, Multicenter Clinical Study of High-dose Furmonertinib in First-line Treatment of EGFR Mutated NSCLC With Central Nervous System), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05379803 phase2recruitingnot on this map

A Single Arm, Multicenter Clinical Study of High-dose Furmonertinib in First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

TypeinterventionalSponsorHunan Province Tumor HospitalRan2022 to 2025Enrolled40ConditionsNon-Small Cell Lung CancerArmsFurmonertinib
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Huan YanEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; College of Clinical Medicine, Qinghai University, Xining 810000, Qinghai, China.
Wenjuan JiangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Yi XiongDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Li LiuDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Renzhi ZhangEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Zhaohui RuanEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Third Xiangya Hospital, Central South University, Changsha 410000, China.
Zhe HuangEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; School of Basic Medicine Sciences, Central South University, Changsha 410078, Hunan, China.
Jiacheng DaiEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Fang TianEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; College of Clinical Medicine, Qinghai University, Xining 810000, Qinghai, China.
Chunhua ZhouDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Zhan WangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Haiyan YangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Wei TaoGenecast Biotechnology Co., Ltd. Wuxi, Wuxi 214000, China.
Hongbo ZhengGenecast Biotechnology Co., Ltd. Wuxi, Wuxi 214000, China.
Qinqin XuCollege of Clinical Medicine, Qinghai University, Xining 810000, Qinghai, China; Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining 810000, China.
Nong YangHunan Provincial Second People's Hospital, Changsha 410013, Hunan, China.
Liang ZengEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. Electronic address: 530490930@qq.com.
Yongchang ZhangEarly Clinical Trial Center, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; College of Clinical Medicine, Qinghai University, Xining 810000, Qinghai, China; Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China; Third Xiangya Hospital, Central South University, Changsha 410000, China; School of Basic Medicine Sciences, Central South University, Changsha 410078, Hunan, China. Electronic address: zhangyongchang@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastases in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) frequently contribute to treatment failure. This phase II study aims to evaluate furmonertinib (160 mg daily) in 40 untreated patients with EGFR-mutant NSCLC and central nervous system (CNS) metastases. At a median follow-up of 18.66 months, the blinded independent central-review-assessed median progression-free survival (mPFS) and intracranial PFS are 16.59 months (95% confidence interval [CI]: 12.77-20.41) and 17.83 months (95% CI: 14.16-21.50), respectively. Systemic objective response rate (ORR) is 92.5%, and intracranial ORR is 95.0%, with consistent investigator assessments. Grade ≥3-treatment-related adverse events occur in 15.0% of patients. Exploratory profiling of paired plasma and cerebrospinal fluid reveals significant early molecular response, with high EGFR mutation clearance (85.7% plasma; 66.7% cerebrospinal fluid [CSF]). Furmonertinib shows promising intracranial efficacy with manageable safety as first-line treatment for EGFR-mutated NSCLC with CNS metastases. This study is registered at ClinicalTrials.gov (NCT05379803).

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCentral Nervous System NeoplasmsLung NeoplasmsMutationAdultAgedBrain NeoplasmsErbB ReceptorsFemaleHumansMaleMiddle AgedProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase Inhibitorscentral nervous system metastasesEGFR mutationfurmonertinibnon-small cell lung cancerthird-generation EGFR-TKI

Identifiers

PMID42379171
PMCPMC13400170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.